Multi modal targets in Psoriasis

Abstract

Psoriasis is a life-long disease that requires long-term treatment. The long-term use of conventional systemic treatments is limited mostly by poor tolerability and cumulative toxicity. Psoriasis significantly impairs the quality of life of patients .In contrast, the long-term use of biologics is more advisable, because of better tolerability and safety, although their cost hinders their clinical usage Evidence suggests that PASI 100 (i.e., complete clearance of psoriasis) may be achievable for many patients with moderate-to severe psoriasis using biologics in development brodalumab and ixekizumab or secukinumab that inhibit interleukin (IL)-17. Keywords: Psoriasis, Inflammation, TCell Activation biologics.